Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Takes Another Leap Into Gene Therapy With Jaguar

Co-leads $139m Fundraising

Executive Summary

Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.

You may also be interested in...



All Over For Servier's Autism Ambitions

The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.

Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel